NCT05811793View on ClinicalTrials.gov

Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.

NANot yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 15, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 30, 2025

Conditions
Glioblastoma
Interventions
DRUG

Tislelizumab and Bevacizumab

Tislelizumab is a drug material authorized for marketing in China. Tislelizumab will be administered off-label in this study. Subjects with recurrent GBM will receive intrathecal tislelizumab every 3 weeks for six times. Intrathecal administration of Bevacizumab will be performed via Ommaya reservoir or intraventricular catheter.

All Listed Sponsors
collaborator

Zhejiang University

OTHER

lead

Second Affiliated Hospital of Nanchang University

OTHER

NCT05811793 - Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma. | Biotech Hunter | Biotech Hunter